(Total Views: 265)
Posted On: 04/11/2023 8:24:49 AM
Post# of 630
$HALB Halberd Begins Preclinical Testing at Mississippi State University (MSU)
https://www.accesswire.com/748456/Halberd-Beg...ersity-MSU
JACKSON CENTER, PA / ACCESSWIRE / April 11, 2023 / Halberd Corporation (OTC PINK:HALB) has announced that preclinical testing is now underway at Mississippi State University (MSU) for its groundbreaking patent-pending nasal spray designed to suppress the negative effects of Traumatic Brain Injury (TBI). This innovative research involves the development of test mechanisms by MSU's staff to quantify and correlate the level of head impact to the degree of resulting brain injury, which has never been done before. Once these critical parameters are established, actual nasal spray testing will commence.
Halberd's approach to preventing the cascade of negative effects in the brain following head trauma is through the use of a proprietary blend of three active ingredients in a nasal spray, designed to block the excess production of certain identified inflammatory cytokines and neurotransmitters. MSU's pre-clinical tests aim to document the improvement in outcomes after brain injury from the administration of the nasal spray within hours of the traumatic event.
Halberd has previously stated that this project is fully funded by Epidemiologic Solutions Corporation, a 501 (c) (3) non-profit charity, enabling Halberd Corporation to proceed without the need for a partnership with Big Pharma or another partner. In compliance with MSU requirements, 75% of the estimated project costs have already been paid. The company is also working with mdi Consultants to ensure that testing and documentation conform to the FDA's strict requirements on the road to market approval.
The potential market for a product that proactively treats TBI through the suppression of excess neurotransmitters or inflammatory cytokines associated with brain trauma is enormous. Currently, no other product on the market addresses this need. If the test results are positive, this will be a significant step towards realizing Halberd's first therapeutic product, with enormous potential.
https://www.accesswire.com/748456/Halberd-Beg...ersity-MSU
JACKSON CENTER, PA / ACCESSWIRE / April 11, 2023 / Halberd Corporation (OTC PINK:HALB) has announced that preclinical testing is now underway at Mississippi State University (MSU) for its groundbreaking patent-pending nasal spray designed to suppress the negative effects of Traumatic Brain Injury (TBI). This innovative research involves the development of test mechanisms by MSU's staff to quantify and correlate the level of head impact to the degree of resulting brain injury, which has never been done before. Once these critical parameters are established, actual nasal spray testing will commence.
Halberd's approach to preventing the cascade of negative effects in the brain following head trauma is through the use of a proprietary blend of three active ingredients in a nasal spray, designed to block the excess production of certain identified inflammatory cytokines and neurotransmitters. MSU's pre-clinical tests aim to document the improvement in outcomes after brain injury from the administration of the nasal spray within hours of the traumatic event.
Halberd has previously stated that this project is fully funded by Epidemiologic Solutions Corporation, a 501 (c) (3) non-profit charity, enabling Halberd Corporation to proceed without the need for a partnership with Big Pharma or another partner. In compliance with MSU requirements, 75% of the estimated project costs have already been paid. The company is also working with mdi Consultants to ensure that testing and documentation conform to the FDA's strict requirements on the road to market approval.
The potential market for a product that proactively treats TBI through the suppression of excess neurotransmitters or inflammatory cytokines associated with brain trauma is enormous. Currently, no other product on the market addresses this need. If the test results are positive, this will be a significant step towards realizing Halberd's first therapeutic product, with enormous potential.
(0)
(0)
